|Bid||2.96 x 100|
|Ask||2.99 x 500|
|Day's Range||2.93 - 3.10|
|52 Week Range||1.65 - 6.50|
|PE Ratio (TTM)||-0.60|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Looking for obesity-drug stocks to buy? Check out the biggest and best: Eisai, Novo Nordisk, and Roche.
On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.
SAN DIEGO, May 16, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX) announced today that the company will present two oral presentations on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in the European Union, at the 24th European Congress on Obesity (ECO) in Porto, Portugal on May 17 – 20, 2017. Orexigen is committed to leveraging its extensive alliance management capabilities to make Contrave/Mysimba available to patients who struggle to lose weight around the world. The company has entered into strategic partnerships covering 44 countries outside the U.S.